NOVEL INOSITOGLYCANES, METHOD OF OBTAINING THEM, PHARMACEUTIC AGENT, METHOD OF MANUFACTURING SAME AND APPLICATION OF SUCH NOVEL INOSITOGLYCANES IN MANUFACTURE OF PHARMACEUTIC AGENT USEFUL IN TREATING DIABETES

摘要

Inositol glycan derivatives of formula (I), their salts and stereoisomeric forms, are new: A-Z-R (I) A = HP(=O)(OH), HP(=S)(OH), HOP(=S)(OH), HSP(=S)(OH), (1-4C alkyl)P(=O)(OH), (1-4C alkyl)P(=S)(OH), SO2ORl, S(=O)OR1, NH2CO, NR1R2, R1R2NCONH, R1OSO2NH, (1-4C alkyl)SO2, (1-4C alkyl)S(=O) or R1S; R1, R2 = H or 1-4C alkyl; Z = 2-6 sugar residues (optionally substituted by up to 6 Me, sugar residue, di-sugar residue, SO2OH, CONR1R2, CO(1-4C alkyl), P(=O)(H)OH, P(=O)(OH)2, P(=S)(H)OH, P(=S)(OH)2, P(=S)(SH)(OH), P(=O)(OH)OCH2CH2NR1R2), or the glycosidic bridge between the 2-6 sugar residues may be 1-6 fold replaced by CH2 or S; R = inositol, inositol phosphate, inositol thiophosphate, inositol cyclo-phosphate, inositol cyclo-thiophosphate (optionally substituted by 1-2 phosphate or thiophosphate, or single substitution by cyclo-phosphate or cyclo-thiophosphate), or inositol (where two neighbouring OH groups are replaced by CH2SO2NH).